Major Depressive Disorder (MDD)Depressive DisordersPTSDKetaminePlacebo

Prophylactic Ketamine Attenuates Learned Fear

This saline-controlled rodent study evaluates whether ketamine (30 mg/kg) is effective in reducing fear or preventing fear reactivation using a contextual fear conditioning (CFC) paradigm. The study found ketamine as most useful in the clinic if administered in a prophylactic manner a week prior to a stressor to protect against increased fear responses to aversive stimuli.

Authors

  • Mcgowan, J. C.
  • Lagamma, C. T.
  • Lim, S. C.

Published

Neuropsychopharmacology
individual Study

Abstract

Ketamine has been reported to be an efficacious antidepressant for major depressive disorder and posttraumatic stress disorder. Most recently, ketamine has also been shown to be prophylactic against stress-induced depressive-like behavior in mice. It remains unknown, however, when ketamine should be administered relative to a stressor in order to maximize its antidepressant and/or prophylactic effects. Moreover, it is unknown whether ketamine can be prophylactic against subsequent stressors. We systematically administered ketamine at different time points relative to a fear experience, in order to determine when ketamine is most effective at reducing fear expression or preventing fear reactivation. Using a contextual fear conditioning (CFC) paradigm, mice were administered a single dose of saline or ketamine (30 mg/kg) at varying time points before or after CFC. Mice administered prophylactic ketamine 1 week, but not 1 month or 1 h before CFC, exhibited reduced freezing behavior when compared with mice administered saline. In contrast, ketamine administration following CFC or during extinction did not alter subsequent fear expression. However, ketamine administered before reinstatement increased the number of rearing bouts in an open field, possibly suggesting an increase in attentiveness. These data indicate that ketamine can buffer a fear response when given a week before as prophylactic, but not when given immediately before or after a stress-inducing episode. Thus, ketamine may be most useful in the clinic if administered in a prophylactic manner 1 week before a stressor, in order to protect against heightened fear responses to aversive stimuli.

Available with Blossom Pro

Research Summary of 'Prophylactic Ketamine Attenuates Learned Fear'

Introduction

Posttraumatic stress disorder (PTSD) is marked by persistent re-experiencing, hyperarousal and avoidance, and current pharmacological treatments such as selective serotonin reuptake inhibitors (SSRIs) show limited efficacy for many patients. In response, researchers have pursued preventative approaches aimed at enhancing stress resilience to reduce the onset or severity of stress-related psychiatric illnesses. Ketamine, an NMDA receptor antagonist with rapid antidepressant effects that can last 1–2 weeks after a single dose, has previously been reported by the study team to act prophylactically against stress-induced depressive-like behaviours in rodent models, and other groups have reported related findings in rats and clinical contexts for PTSD with mixed replication. This study set out to determine how the timing of a single ketamine administration relative to a fear-inducing experience affects subsequent fear expression. Using a contextual fear conditioning (CFC) paradigm in mice, the investigators systematically varied when ketamine (30 mg/kg, i.p.) or saline was given — before or after conditioning, before extinction, and before or after reinstatement — to identify time windows in which ketamine might reduce fear expression, alter extinction, or influence related behaviours such as locomotion, rearing (an index of attentiveness/exploration) and behavioural despair in the forced swim test. The authors hypothesised that ketamine would be prophylactic at some time points but ineffective or possibly deleterious at others.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (4)

Papers cited by this study that are also in Blossom

Antidepressant effects of ketamine in depressed patients

Berman, R. M., Cappiello, A., Anand, A. et al. · Biological Psychiatry (2000)

Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder

Feder, A., Parides, M. K., Murrough, J. W. · JAMA Psychiatry (2014)

528 cited
The correlation between ketamine and posttraumatic stress disorder in burned service members

Mcghee, L. L., Maani, C. V., Garza, T. H. et al. · Journal of Trauma Injury Infection and Critical Care (2008)

Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial

Murrough, J. W., Iosifescu, D. V., Chang, L. C. et al. · American Journal of Psychiatry (2013)

Cited By (6)

Papers in Blossom that reference this study

Psychedelic-Inspired Approaches for Treating Neurodegenerative Disorders

Olson, D. E. · Journal of Neurochemistry (2021)

Ketamine For Post-Traumatic Stress Disorders And Its Possible Therapeutic Mechanism

Asim, M., Wang, B., Hao, B. et al. · Neurochemistry International (2021)

Ketamine anesthesia enhances fear memory consolidation via noradrenergic activation in the basolateral amygdala

Morena, M., Colucci, P., Mancini, G. F. et al. · Neurobiology of Learning and Memory (2021)

16 cited
Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial

Taylor, J. H., Landeros-Weisenberger, A., Coughlin, C. et al. · Neuropsychopharmacology (2017)

115 cited

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.